Colchicine 500 microgram tablets are taken by mouth for gout flares, gout-flare prevention, and familial Mediterranean fever. It reduces inflammation by limiting neutrophil movement and inflammasome…
Colchicine 500 microgram tablets are taken by mouth for gout flares, gout-flare prevention, and familial Mediterranean fever. It reduces inflammation by limiting neutrophil movement and inflammasome signalling, rather than lowering uric acid directly.
Colchicine contains colchicine, an anti-inflammatory medicine derived from Colchicum autumnale. Its established uses include acute gout flares, prevention of recurrent gout flares, and familial Mediterranean fever (FMF).
Colchicine contains colchicine, an anti-inflammatory medicine derived from Colchicum autumnale. Its established uses include acute gout flares, prevention of recurrent gout flares, and familial Mediterranean fever (FMF). The United States Food and Drug Administration recognises these clinical indications, while rheumatology guidance places colchicine within a wider gout-management plan that may also include urate-lowering treatment [1].
During a gout flare, monosodium urate crystals activate immune cells inside a joint. Colchicine reduces the inflammatory response to those crystals. It does not remove uric acid from the blood and does not replace long-term urate-lowering treatment such as allopurinol.
Colchicine may be used in two different ways:
The regimen for this 500 microgram tablet strength must be confirmed with a healthcare professional before starting. Colchicine has a narrow safety margin, so taking extra tablets to obtain faster relief can cause serious poisoning.
FMF is an inherited autoinflammatory condition that can cause recurrent fever, abdominal pain, chest pain, joint inflammation, and inflammation around internal organs. Regular colchicine reduces attacks in many patients and helps lower the risk of amyloidosis, a complication caused by abnormal protein deposits.
Treatment for FMF is usually scheduled rather than taken only when symptoms appear. Missing doses can allow inflammation to return even when the patient feels well. The suitable daily regimen depends on age, kidney function, liver function, pregnancy status, and response to treatment.
Colchicine tablets contain colchicine, an anti-inflammatory medicine derived from Colchicum autumnale. The 500 microgram strength is taken by mouth for acute gout flares, prevention of recurrent gout flares, and familial Mediterranean fever. It works by limiting neutrophil movement and inflammasome signalling rather than lowering uric acid directly.
Colchicine enters inflammatory cells and binds to tubulin, a protein required to form microtubules. Microtubules act like internal tracks that help neutrophils move, change shape, and release inflammatory substances. By disrupting this process, colchicine reduces the migration of neutrophils toward urate crystals.
The medicine also affects signalling linked with the NLRP3 inflammasome. This immune complex contributes to the release of interleukin-1β, a cytokine strongly involved in gout inflammation. Reduced neutrophil activity and lower interleukin-1β signalling help explain why colchicine can calm an attack without directly changing uric acid concentration.
| Pharmacological feature | Clinical meaning |
|---|---|
| Tubulin binding | Limits microtubule activity inside inflammatory cells |
| Neutrophil inhibition | Reduces movement of immune cells into inflamed joints |
| NLRP3 and interleukin-1β signalling | Dampens part of the inflammatory cascade |
Colchicine tablets are taken orally.
The regimen for the 500 microgram strength is confirmed with a healthcare professional before starting because the correct schedule changes according to the indication and the patient’s kidney, liver, and interacting medicines.
Key administration principles include:
A missed dose requires an indication-specific decision. For a scheduled preventive regimen, the next dose may be taken when remembered if it is not close to the next scheduled dose. For an acute flare regimen, repeating or adding doses can be unsafe, so the prescriber’s instructions take priority.
Colchicine belongs to a different pharmacological category from medicines that lower uric acid or suppress inflammation through other pathways.
| Approach | Main role |
|---|---|
| Colchicine | Controls inflammation linked with gout crystals and supports FMF control |
| Allopurinol-based urate lowering | Reduces uric acid production for long-term gout prevention |
| Corticosteroid treatment | Suppresses inflammation during selected acute attacks |
Colchicine can be paired with allopurinol because the two medicines address different parts of gout. Colchicine reduces inflammatory activity, while allopurinol lowers uric acid production over time. A patient should not judge allopurinol failure by the presence of an early flare; attacks can occur while urate levels are being brought under control.
Corticosteroids may be selected when colchicine is unsuitable because of kidney impairment, interacting medicines, intolerance, or clinical circumstances. The choice depends on the joint involved, the number of affected joints, infection risk, diabetes, blood pressure, and previous treatment response.
Several avoidable errors reduce benefit or increase risk:
A common misconception is that stronger gastrointestinal symptoms show that colchicine is working better. They do not. Increasing diarrhoea or vomiting may signal excessive exposure and requires prompt medical attention.
Colchicine should not be used with strong CYP3A4 or P-glycoprotein inhibitors when kidney or liver function is impaired. It also requires careful assessment in patients with:
Colchicine is metabolised partly through CYP3A4 and is a substrate of P-glycoprotein. These pathways influence how much medicine reaches the bloodstream and how quickly it is cleared.
| Interacting factor | Potential consequence |
|---|---|
| Clarithromycin and other strong CYP3A4 inhibitors | Higher colchicine exposure and severe toxicity risk |
| P-glycoprotein inhibitors | Reduced cellular transport and increased systemic exposure |
| Grapefruit or grapefruit juice | May increase exposure through intestinal enzyme and transporter effects |
Clarithromycin deserves special attention. It inhibits CYP3A4 and can produce a dangerous rise in colchicine concentration, especially in older adults or people with reduced kidney function. Other macrolide antibiotics may require similar caution, so the prescriber should know about any antibiotic being considered.
Grapefruit juice should be avoided unless a clinician has specifically assessed the combination. The same applies to supplements or herbal products that affect CYP3A4 or P-glycoprotein.
NOT for you if you have severe kidney or liver impairment, take interacting medicines, or cannot follow the prescribed regimen; seek prescriber advice before use. The decision requires a review of kidney function, liver function, age, pregnancy status, and the full medicine list.
Gastrointestinal effects are the most familiar adverse reactions. Nausea, vomiting, abdominal pain, and diarrhoea may occur, especially when the dose is too high or the patient is unusually sensitive. Diarrhoea can be an early sign that exposure is excessive rather than a harmless inconvenience.
More serious toxicity can affect the blood, nerves, muscles, kidneys, and liver. Myopathy may cause muscle aching or weakness. Rhabdomyolysis is a severe form of muscle injury that can release muscle proteins into the bloodstream and damage the kidneys.
Seek urgent medical assessment for:
The FDA prescribing information describes gastrointestinal toxicity, blood-cell abnormalities, neuromuscular toxicity, and interactions that can raise colchicine exposure [2].
One practical detail is easy to miss: muscle symptoms may be more likely when colchicine is combined with a statin or another medicine that can injure muscle. The risk rises further with kidney impairment. A patient who develops new weakness should report every medicine being taken, including treatments used only occasionally.
In clinical practice, doctors usually frame colchicine as a dose-sensitive anti-inflammatory rather than a general painkiller. It works best when the regimen matches the indication and when kidney function and interacting medicines have been reviewed before treatment begins.
A rheumatology clinician would often explain that colchicine does not dissolve urate crystals and does not lower serum uric acid. The medicine controls the inflammatory reaction caused by the crystals. Long-term gout control still depends on managing urate levels, diet-related triggers, kidney health, and other cardiovascular risk factors.
Doctors also look for patterns in tolerability. Mild stomach upset may require a dosing review, while continuing diarrhoea, weakness, or muscle pain can indicate clinically significant toxicity. In older adults, a medication review is essential because several ordinary prescriptions can combine to raise colchicine exposure.
Severe diarrhoea, repeated vomiting, marked weakness, muscle pain, dark urine, numbness, unusual bruising, or signs of infection require urgent medical assessment. These symptoms can indicate gastrointestinal toxicity, myopathy, rhabdomyolysis, or blood-cell suppression. Do not take additional doses while waiting for clinical advice. EMA safety information in 2024 continued to treat severe gastrointestinal and neuromuscular symptoms as warning signs requiring prompt evaluation.
The course depends on whether Colchicine is being used for an acute gout flare, short-term flare prevention, or ongoing familial Mediterranean fever control. Long-term use can be appropriate for FMF and for selected gout-prevention plans when kidney function, liver function, blood counts, interactions, and symptoms are reviewed. It is not appropriate to extend a course independently after the original treatment period. The American College of Rheumatology guidance published in 2020 supports indication-based colchicine use within a broader gout strategy.
A single dose does not provide a fixed period of pain relief in the same way as a conventional analgesic. Its effect depends on the inflammatory process, the timing of treatment, kidney and liver clearance, and the dosing schedule prescribed for the specific indication. Repeating a dose sooner than instructed can increase toxicity without producing proportionally better relief. Pharmacokinetic data reviewed by the FDA in 2024 support caution because exposure can rise substantially when clearance is reduced or metabolism is inhibited.
Discuss kidney disease, liver disease, pregnancy or breastfeeding, blood disorders, muscle disease, and every prescription or non-prescription medicine being used. Mention statins, antibiotics, antifungals, transplant medicines, heart medicines, and grapefruit consumption because some can alter colchicine exposure. The regimen for the 500 microgram tablet strength should be confirmed before treatment begins. MOHAP medicine-safety principles in 2025 supported medication reconciliation before starting treatments with important interaction risks.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
